Key Summary Points {#FPar1}
==================

**Why carry out this study?**Despite the availability of effective asthma treatments, some individuals are poorly controlled because of overreliance on short-acting β~2~-agonists (SABAs) and underuse of inhaled corticosteroids.As a result of growing evidence that SABA overreliance is associated with an increased risk of asthma-related exacerbations and mortality, a global view of SABA prescriptions is needed to better understand the public health burden of SABA overuse in asthma management.As part of the SABINA (SABA use IN Asthma) program, this study aimed to provide an overview of similarities and differences in SABA prescription trends across five European countries (UK, Germany, Italy, Spain, and Sweden) in over one million individuals.**What was learned from the study?**SABA overuse (≥ 3 canisters per year) occurred in approximately one-third of mild, moderate, and severe individuals with asthma across Europe, despite the different healthcare and reimbursement policies of each country.These findings indicate that there is a significant group of individuals who are not optimally treated according to current recommendations.Following the recent 2019 Global Initiative for Asthma (GINA) update, which no longer recommends treating adolescents and adults with as-needed SABA alone for symptom relief, changes in physician and patient behaviors towards SABA use, and updates to national healthcare policies, are required to ensure that individuals with asthma are not exposed to SABA alone in the treatment of their asthma.

Introduction {#Sec1}
============

Asthma is a chronic, heterogeneous, fluctuating, inflammatory disease of the airways that is estimated to affect 339 million people worldwide \[[@CR1]\]. In Europe, over 8% of adults have asthma, with the highest prevalence found in the United Kingdom (UK) and Sweden \[[@CR1]--[@CR3]\]. Anti-inflammatory maintenance treatment with low-dose inhaled corticosteroids (ICS) is the cornerstone of asthma treatment \[[@CR4]\]. As-needed short-acting β~2~-agonists (SABAs) have been traditionally prescribed for symptom relief, with or without daily maintenance treatment, depending on the level of asthma severity \[[@CR5], [@CR6]\]. However, evidence on the safety risks associated with high SABA use has grown substantially in the last few years \[[@CR7]--[@CR10]\]. In parallel, clinical trials have reported the superiority of anti-inflammatory reliever therapy with as-needed ICS--formoterol versus as-needed SABA in terms of symptom control and reduction in exacerbation risk \[[@CR11]--[@CR15]\]. Consequently, the 2019 Global Initiative for Asthma (GINA) recommendations have eliminated SABA monotherapy in step 1 and instead recommend as-needed low-dose ICS--formoterol as the preferred reliever in steps 1--2. In addition, in GINA steps 3--5, low-dose ICS--formoterol is the preferred reliever for patients prescribed ICS--formoterol maintenance and reliever therapy \[[@CR16]\].

With this knowledge, SABA overreliance is now an even greater concern. However, it will be difficult to change this overreliance, linked to decades of patient behavior and guidelines recommending, until very recently, SABA use for immediate symptom relief and as the first treatment for newly diagnosed mild intermittent asthma \[[@CR17], [@CR18]\]. When symptoms worsen, most individuals with asthma overrely on their SABA inhaler for symptomatic relief, often at the expense of ICS maintenance therapy \[[@CR19]--[@CR21]\]. As SABAs have no anti-inflammatory effect \[[@CR22], [@CR23]\], they neither treat the underlying inflammation nor protect against exacerbations. The continued reliance on SABA relievers leaves individuals across all asthma severities at risk of preventable attacks whether adherent or not to their maintenance controller \[[@CR11], [@CR14]\]. Indeed, in the UK, SABA overuse and the relative underuse of ICS was highlighted as one of the underlying reasons for preventable asthma attacks and deaths \[[@CR24]\].

There are limited data on SABA and ICS prescription trends in European countries, and a pan-European view of potential SABA overuse and relative ICS underuse is lacking. The SABA use IN Asthma (SABINA) program \[[@CR25]\] was therefore initiated to describe the global extent of SABA and ICS use in asthma and its clinical consequences. For the purpose of this analysis, which was to understand the current state of asthma reliever prescriptions relative to recent treatment recommendations, we aimed to provide an overview of the similarities and differences in SABA prescription trends only, for individuals with asthma across European countries.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

The SABINA program encompasses three main pillars: SABINA I (a retrospective, observational database study with expanded objectives in the UK), SABINA II (a distributed harmonized set of multicountry retrospective observational database studies in Europe and Canada), and SABINA III (a prospectively collected multicountry cross-sectional study in 25 countries). Full details of the SABINA program are described elsewhere \[[@CR25]\]. In this study, prescription data generated from the European arms of SABINA---SABINA I (UK) and SABINA II (Italy, Germany, Spain, and Sweden)---were analyzed. On the basis of data availability, individual country data were obtained from electronic medical records and/or national patient registries as shown in Table [1](#Tab1){ref-type="table"}.Table 1Study design features in SABINA I and IISABINA I (UK)SABINA IIGermanyItalySwedenSpainData sourcePrimary care records (CPRD GOLD), linked with secondary care (HES) and mortality (ONS) dataIMS^®^ Disease Analyzer: electronic medical records from general practitioner and pulmonologist panelsIQVIA^®^ databases: electronic medical records from primary care (Longitudinal Patient Database) and secondary care (Patient Analyzer) physiciansNationwide longitudinal cohort study (HERA): linked data from national patient, pharmacy dispensing, and mortality registriesBIG-PAC^®^ database: electronic medical records from primary and specialized healthcareStudy period2007--20172013--20182015--20182006--20162017--2018Age≥ 12 years≥ 12 years≥ 12 years12--45 years≥ 12 yearsAsthma definitionAsthma diagnosis code within 3 years of index dateAsthma diagnosis code during study periodAsthma diagnosis code 1 year prior to index date≥ 2 collections for a chronic obstructive pulmonary disease medication within 12 monthsAsthma diagnosis code and ≥ 2 healthcare uses within study periodAsthma treatment steps2016 BTS guidelines2018 GINA recommendations2018 GINA recommendations2018 GINA recommendations2018 GINA recommendations*BTS* British Thoracic Society, *CPRD* Clinical Practice Research Datalink, *GINA* Global Initiative for Asthma, *HERA* High Efficiency Reliable Access (to data stores), *HES* Hospital Episode Statistics, *ONS* Office for National Statistics, *SABINA* SABA use IN Asthma

Patient Population {#Sec4}
------------------

Individuals aged at least 12 years old with a current asthma diagnosis were included in the study. In Sweden, the study population included all individuals with asthma who collected at least two drugs for obstructive lung disease (ATC R03) from pharmacies in a 1-year period. In addition, the upper age limit of 45 years was applied in Sweden to ensure that individuals with chronic obstructive pulmonary disease (COPD) were excluded, a validated proxy for asthma \[[@CR26]\]. The definition of current asthma varied across studies (Table [1](#Tab1){ref-type="table"}). For instance, in most countries, current asthma was defined as an asthma diagnosis code within 1 or 3 years before the index date (date on which the individual first entered the study); however, in Sweden, it was defined as at least two prescriptions for a chronic obstructive lung disease medication within 12 months of study entry. All studies required individuals with asthma to have data for at least 12 months before and after study entry. Study periods varied between 2006 and 2018. However, all countries included recent data (2016--2018) on SABA use, while some countries, such as Sweden and the UK, included data from as early as 2006.

The studies performed as part of the SABINA program were each approved by the institutional review board of the ethics committee in their individual country and were conducted in accordance with the Declaration of Helsinki of 1964 and its later amendments, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), Good Clinical Practice (GCP), and the applicable legislation on non-interventional studies and/or observational studies.

Study Measures {#Sec5}
--------------

### SABA Use {#Sec6}

The percentage of individuals with asthma who were prescribed SABA was recorded during a 12-month period. SABA use was categorized by the number of canister prescriptions per year (0--2, 3--6, 7--12, or 13 and more). According to the guidelines, appropriate use of SABA is considered as fewer than three puffs per week, which is equivalent to fewer than 150 puffs/actuations per year or at most two prescribed canisters per year. For consistency across all countries in the SABINA program, one SABA canister was assumed to contain 150 inhalations \[[@CR25]\]. However, in Germany and Spain, one canister was defined as containing 200 inhalations based on a preliminary analysis of the data, which showed that nearly all prescribed SABA canisters contained 200 doses. On the basis of this assumption and allowing for individuals to have multiple SABA inhalers at the same time, SABA overuse was defined as prescription/dispensing of at least three canisters per year.

### Treatment Step and Asthma Severity {#Sec7}

Individuals with asthma were categorized into treatment steps (1--5) and severity (mild, steps 1--2; moderate--severe, steps 3--5) by their ICS prescriptions (low, medium, or high) in the year prior to their index date on the basis of the 2016 British Thoracic Society (BTS) guidelines \[[@CR6]\] (low-dose ICS, 400--799 µg beclometasone dipropionate \[BDP\] equivalent; medium-dose ICS, 800--1599 µg; high-dose ICS, at least 1600 µg) for the UK or 2018 GINA recommendations \[[@CR5]\] (low-dose ICS, 200--500 µg BDP equivalent; medium-dose ICS, 500--1000 µg BDP equivalent; high-dose ICS, more than 1000 µg BDP equivalent) for the remaining countries.

Statistical Analysis {#Sec8}
--------------------

Baseline characteristics were described as mean (standard deviation, SD) for continuous variables and absolute and relative frequencies for categorical variables. Descriptive statistics were provided for the SABA prescription data.

Results {#Sec9}
=======

Patient Baseline Demographics and Clinical Characteristics {#Sec10}
----------------------------------------------------------

Overall, 1.06 million individuals with asthma were included across the countries. On average, most individuals were at least 45 years of age, except in Sweden where the mean age of individuals was 27.6 years (Table [2](#Tab2){ref-type="table"}). Most individuals with asthma were female, except in the UK, where male individuals constituted the majority (54%). The severity of asthma (as determined by treatment step) varied across countries. In Germany and the UK, most of the study population included were treated as having mild asthma (60% and 65%, respectively). In Italy and Spain, most individuals had moderate-to-severe asthma (63% and 73%, respectively), while in Sweden, they were distributed almost equally across severities.Table 2Baseline characteristics of individuals with asthmaItalyGermanySpainSwedenUKTotal number of included individuals with asthma22,10253,86639,555365,324574,913Mean age in years at study entry (SD)50.8(19.1)51.0(18.0)49.8(20.7)27.6(11.0)50.0(20.6)Male gender (%)4240364554Individuals with mild asthma (treatment step^a^ 1--2) (%)37602748^b^65Individuals with moderate-to-severe asthma (treatment step^a^ 3--5) (%)6340735035*BTS* British Thoracic Society, *GINA* Global Initiative for Asthma, *SD* standard deviation^a^Treatment steps were based on GINA 2018 for all countries, except the UK (BTS 2016)^b^Approximately 2% of individuals could not be classified into a GINA therapy step in Sweden

SABA Use {#Sec11}
--------

The characteristics of SABA use are summarized in Table [3](#Tab3){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}. The mean number of annual SABA canisters used varied across countries. Overall, the prevalence of SABA overuse was 9% in Italy, 16% in Germany, 29% in Spain, 30% in Sweden, and 38% in the UK. In the UK, SABA overuse was greater in individuals with moderate-to-severe asthma versus mild asthma (58% versus 27%). Overall, SABA overuse was similar in individuals with mild (9--32%) and moderate-to-severe (8--31%) asthma in the other European countries.Table 3Treatment characteristics: overall SABA useItalyGermany^a^SpainSwedenUKMean (SD) number of annual SABA canisters3.1 (4.0)1.6 (3.9)3.3 (3.6)1.9 (2.9)4.2 (5.1)Individuals with 0--2 SABA canisters/year (%)9184717062Individuals with ≥ 3 SABA canisters/year (%)916293038Individuals with 3--6 SABA canisters/year (%)610192524Individuals with 7--12 SABA canisters/year (%)236511Individuals with ≥ 13 SABA canisters/year (%)12414*GP* general practitioner, *SABA* short acting β~2~-agonist, *SD* standard deviation^a^This analysis was based on GP-treated individuals only (*n* = 29,636)Fig. 1SABA use in individuals with mild and moderate-to-severe asthma across European countries. In Germany, analysis was based on GP-treated individuals only (*n* = 29,636). Treatment steps were based on GINA 2018 for all countries, except the UK (BTS 2016). *BTS* British Thoracic Society, *GINA* Global Initiative for Asthma, *GP* general practitioner, *SABA* short-acting β~2~-agonist

Discussion {#Sec12}
==========

SABINA I and II assessed SABA prescription trends across European countries in over a million individuals with asthma. Overall, with the exception of Italy, SABA use was common across all asthma severities, and our data suggest that approximately one-third of individuals are overusing SABA.

Our findings are generally consistent with those of other studies in a European population using the same SABA canister cutoff, but different study designs. In the cross-sectional ASTHMAPOP survey among 15,587 adults in France, 28.3% of patients reported using at least three SABA canisters per year \[[@CR27]\]. Similarly, a Polish study of pharmacy prescription records of 91,673 adult patients observed that 29--37% of patients with asthma were prescribed at least three SABA canisters per year \[[@CR28]\]. Differences in national healthcare and medication reimbursement policies may impact medication prescribing practices and related clinical outcomes, and this needs to be taken into consideration for the present study findings. For instance, SABA is available without a prescription in Italy, Spain, and the UK (emergency access only), but not in Germany and Sweden. Notably, availability of SABA without a prescription has been linked to undertreatment of asthma (relative to the relevant guidelines recommendations) and infrequent consultations with physicians \[[@CR29]\]. Moreover, it has been shown that without regular medical supervision, patients are more likely to overuse SABA \[[@CR30]\]. Although SABA medication is not available without a prescription in many countries in the SABINA program, such findings have far-reaching global implications. Consequently, an improved understanding of this population of individuals with asthma who purchase SABA, especially their attitudes and beliefs about asthma and its treatment, is essential. A recent real-world, cross-sectional observational study in Australia, where SABA medication can be purchased from the community pharmacist without a prescription, identified a cohort of individuals with suboptimal asthma control, co-existing allergic rhinitis, and poor ICS adherence who were SABA overusers (used SABA more than twice a week in the past 4 weeks) \[[@CR31]\]. Addressing such findings in primary care is critical to address the issue of SABA overuse. Because the availability of SABA without prescription was not taken into account in our analysis, actual SABA use may be even higher in countries that do not require a prescription to purchase SABA medication. This finding is particularly apparent in the assessment of SABA prescriptions in Italy in our study, where SABA overuse was less evident compared with other European countries. From initial market research, it is understood that a relatively large proportion of individuals with asthma obtain SABA inhalers without prescription, which could explain the low prevalence of SABA overuse in prescription databases. Further analyses are now planned to investigate this possibility in Italy.

Although similar SABA use trends were observed despite differences across national policies, data sources, and study designs, there were some differences in relation to SABA use and asthma severity. Among the five countries analyzed, the UK had the lowest percentage of individuals receiving treatment for moderate-to-severe asthma, and the highest average number of annual SABA prescriptions. This could indicate that individuals with uncontrolled asthma in the UK are more likely to be prescribed SABA rather than being reviewed and prescribed an increased dose of their maintenance therapy as recommended by guidelines \[[@CR6]\]. Indeed, according to a recent survey among individuals with asthma in the UK, over 60% of respondents indicated that they did not receive basic asthma care, and approximately 20% of respondents did not receive an annual asthma review \[[@CR32]\].

Exposure and adherence to maintenance ICS will likely impact SABA use, and it is, therefore, important to put these findings into the context of ICS exposure. SABA overuse was greater in individuals with moderate-to-severe asthma (up to 58%) compared with individuals with mild asthma, suggesting a greater degree of poor asthma control in these individuals despite receiving maintenance ICS to treat the underlying inflammation. Similar results were reported from the recent Polish pharmacy prescription study, in which patients on a higher treatment step received more SABA prescriptions compared with patients on lower treatment steps \[[@CR28]\]. It is possible that low ICS adherence is a driving factor or that maintenance therapy exposure is simply an indication of disease severity and of an increased likelihood of the presence of symptoms that require SABA. More detailed analyses in the individual SABINA studies are underway to investigate the potential association of ICS and SABA use.

Overall, our findings indicate that there is considerable SABA use---and indeed SABA overuse---among individuals across Europe, which puts them at risk of adverse outcomes. Changes in physician and patient behaviors towards SABA use, active engagement in adapting 2019 GINA recommendations to local guidelines, and updates to national healthcare policies will be needed to ensure that individuals with asthma are not unnecessarily exposed to SABA alone in the treatment of their inflammatory disease. Physicians should encourage the appropriate use of ICS, eliminate SABA monotherapy as per evidence-based recommendations, challenge patient attitudes and practices around SABA use, and ensure that individuals understand that asthma is an inflammatory condition. Importantly, individuals should be trained on the appropriate use of therapy \[[@CR33]\] and the technical use of inhalers \[[@CR34]\]. Asthma education programs discouraging unregulated SABA use should be given due consideration. Education, together with regular medical reviews and written personal asthma action plans, is advocated in guidelines and has been shown to improve health outcomes for individuals with asthma \[[@CR35]\]. Therefore, a drive to implement personal actions plans, describing how patients may recognize a deterioration in asthma control and what steps should be taken to re-establish control \[[@CR36]\], could further assist in curbing SABA overuse. Other healthcare professionals, such as nurses and pharmacists, could also provide training and support to patients. Pharmacists can also play an integral role as they are in the unique position of being able to initiate conversations about SABA overuse and can spend time educating patients and answering any questions \[[@CR31]\].

Potential limitations of this analysis relate to the observational nature of the included studies and the use of medical databases that were not necessarily designed for research purposes. However, the results were comparable to those from the UK arm of SABINA, which used research-quality data from the Clinical Practice Research Datalink \[[@CR37]\]. This increases confidence in the robustness of the data across the rest of the countries. Additionally, the upper age limit of 45 years in Sweden may have led to more individuals with severe asthma being excluded from the analysis. However, the algorithm that was used to identify individuals with asthma based on pharmacy collection of drugs (ATC R03) for obstructive lung disease was shown to be a suitable proxy for asthma diagnosis in this age group in validation studies from Sweden \[[@CR26]\]. This restriction was not necessary in other countries, where other validated algorithms were used (e.g., the UK) \[[@CR38]\], and where sensitivity analyses were conducted to exclude individuals with a COPD co-diagnosis. Despite these differences, similar overall trends were seen across the countries, indicating that the age restriction applied to Sweden may have had limited impact on the results. Of note, dispensed or prescribed SABA may not always equal the medication taken and may lead to an overestimation of actual SABA overuse. Automatic repeat prescriptions, or simultaneous prescriptions of multiple SABA canisters, may result in individuals having more SABA inhalers in their possession, which they may not necessarily use. From clinical experience, we know that individuals with asthma typically have multiple SABA inhalers such that there is at least one inhaler in each of their surroundings (e.g., home, office, car). This is done so that individuals with asthma have immediate access to their reliever in the event of a sudden worsening in symptoms. Despite these limitations, the current manuscript assessed a large asthma population across five countries and provides important insights regarding SABA use and the extent of SABA overuse. The use of standardized thresholds for SABA overuse in the SABINA program enabled comparisons across countries, which were previously limited by the varying SABA overuse thresholds used across published studies \[[@CR39]--[@CR41]\]. The next steps for the program are to describe SABA use across additional countries, and to investigate the association of SABA use, maintenance ICS therapy, and clinical outcomes with healthcare resource use. Additionally, further context around patient's quality of life and patient's adherence behaviors will provide important insights into how to better interpret the program findings and how to potentially decrease SABA use in the future. More in-depth analyses should be performed in those countries that are involved in the SABINA program.

Conclusions {#Sec13}
===========

There is a growing body of evidence that high SABA use is associated with increased risk of adverse asthma-related outcomes. Individuals across all asthma severities remain at risk of exacerbations when they continue to overrely on SABA at the expense of ICS, leaving the underlying inflammation undertreated. Data from the SABINA program demonstrated that a considerable proportion of individuals with asthma across Europe are using at least three SABA canisters per year, indicating that there is a significant group of individuals who are currently not optimally treated according to the 2019 GINA recommendations. The combination of an ICS/fast-onset but long-acting β~2~-agonist will be an effective patient-friendly strategy for improving adherence to evidence-based guidelines. Further work to support changes to national treatment guidelines and, therefore, ensure successful implementation of the latest GINA recommendations is currently underway.
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